Proliferative Diabetic Retinopathy Clinical Trial
Official title:
Gene Expression and Their Correlations in Patients With Idiopathic and Secondary Epiretinal Membranes in Proliferative Diabetic Retinopathy
Verified date | September 2013 |
Source | Medical University of Silesia |
Contact | n/a |
Is FDA regulated | No |
Health authority | Poland: Ethics Committee |
Study type | Observational |
The purpose of this study was to investigate the expression of selected genes both in epiretinal membranes (ERMs) and peripheral blood mononuclear cells (PBMCs) from patients with primary and secondary epiretinal membranes in proliferative diabetic retinopathy. Possible correlations between messenger ribonucleic acid (mRNA) levels of these genes were also identified.
Status | Active, not recruiting |
Enrollment | 0 |
Est. completion date | December 2013 |
Est. primary completion date | September 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 55 Years and older |
Eligibility |
Inclusion Criteria: - Caucasian race, - both males and females, - aged = 55 years, - suffering from idiopathic ERMs or secondary ERMs in proliferative diabetic retinopathy (PDR). - Presence of ERM was proven in optical coherence tomography (OCT) examination. Exclusion criteria: - aged < 55 years, - systemic connective tissue disease, - active inflammatory process |
Observational Model: Case Control, Time Perspective: Retrospective
Country | Name | City | State |
---|---|---|---|
Poland | Medical University of Silesia | Katowice |
Lead Sponsor | Collaborator |
---|---|
Medical University of Silesia |
Poland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Gene expression in patients with idiopathic and secondary epiretinal membranes in proliferative diabetic retinopathy. | The period between the diagnosis of the ERMs and the actual surgery for the condition was between 2 and 43 months. | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01921192 -
Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy
|
Phase 4 | |
Recruiting |
NCT01044875 -
Trial of Yellow 577 nm Laser Versus Green 532 nm Laser for Proliferative Diabetic Retinopathy
|
N/A | |
Active, not recruiting |
NCT00993525 -
Intravitreal Ranibizumab For Persistent New Vessels In Diabetic Retinopathy(Inipe Study)
|
Phase 1/Phase 2 | |
Completed |
NCT01307072 -
Compliance to Ophthalmic Follow-up Examinations and Surgical Outcome for Proliferative Diabetic Retinopathy
|
N/A | |
Completed |
NCT01758757 -
Comparison of Small-gauge Vitrectomy and Conventional Vitrectomy for Proliferative Diabetic Retinopathy
|
N/A | |
Withdrawn |
NCT00600236 -
HLA and it Relation With the Development of Proliferative Diabetic Retinopathy in Mexican Population
|
Phase 3 | |
Completed |
NCT05408416 -
Comparison of Surgery Outcome Between Preoperative IVR and Intraoperative IVR in PPV for PDR
|
N/A | |
Completed |
NCT05414149 -
Efficacy and Safety Comparison of IVR and IVC Before Vitrectomy in Proliferative Diabetic Retinopathy
|
N/A | |
Not yet recruiting |
NCT04464694 -
Pre-vitrectomy Intravitreal Ranibizumab for Patients With Proliferative Diabetic Retinopathy Combined With Diabetic Macular Edema
|
Phase 4 | |
Not yet recruiting |
NCT03633266 -
Anti-VEGF Instead of Intraoperative PRP in Proliferative Diabetic Retinopathy
|
N/A | |
Completed |
NCT03490318 -
Effectiveness of Multimodal Imaging for the Evaluation of Retinal Oedema And New vesseLs in Diabetic Retinopathy
|
||
Completed |
NCT01627977 -
Association of Lutein, Zeaxanthin and Brilliant Blue in Chromovitrectomy
|
Phase 3 | |
Completed |
NCT00776763 -
Ocular Growth Factors Profile in Proliferative Retinopathies Before and After Intravitreal Bevacizumab
|
Phase 2 | |
Terminated |
NCT00563628 -
Changes in Macular Thickness After Patterns Scan Laser
|
Phase 4 | |
Completed |
NCT00682240 -
Morphological and Functional Retinal Changes Following Retinal Photocoagulation
|
Phase 4 | |
Terminated |
NCT00563043 -
Changes in Electroretinogram and Contrast Sensitivity After PASCAL Treatment
|
Phase 4 | |
Completed |
NCT00446381 -
Effect of Macugen(Pegaptanib)on Surgical Outcomes and VEGF Levels in Diabetic Patients With PDR (Diabetic Retinopathy or CSDME (Macular Edema)
|
N/A | |
Completed |
NCT02879422 -
Genetic Markers and Proliferative Diabetic Retinopathy
|
N/A | |
Enrolling by invitation |
NCT02911311 -
Conbercept vs Panretinal Photocoagulation for the Management of Proliferative Diabetic Retinopathy
|
N/A | |
Recruiting |
NCT05514925 -
Cryoapplication Versus Anti-VEGF Before Diabetic Vitrectomy
|
Phase 4 |